key: cord-0868045-eztq6xp9
authors: Aubignat, Mickael; Godefroy, Olivier
title: COVID-19 and ischemic stroke: should we systematically look for lupus anticoagulant and antiphospholipid antibodies?
date: 2020-05-08
journal: Rev Neurol (Paris)
DOI: 10.1016/j.neurol.2020.05.001
sha: e14edc3a047733aea6ed402aabf164258afd6b47
doc_id: 868045
cord_uid: eztq6xp9

nan

Coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly throughout the globe [1] . The spectrum of disease is broad ranging from asymptomatic cases to multi-organs failures. The main impairment is respiratory with: dry cough, dyspnea or acute respiratory distress syndrome. However, neurological impairments are also described including: headache, hyposmia, hypogeusia, dizziness, impaired consciousness, seizure, encephalopathy, neuromuscular injury or acute cerebrovascular disease [2] . In a Chinese retrospective study of 214 COVID-19 patients, 78 (36.4%) had neurologic manifestations [3] . Incidence of ischemic stroke in context of COVID-19 varies according preliminary studies from 2.5 to 6.4% [3] [4] [5] [6] .

Many studies reporting that the behavior of clotting variables and platelet count in COVID-19 patients suggest a hyper-coagulation state associated with a significant increased risk of thromboembolic events [7] . A recent meta-analysis suggests that elevated plasma levels of Ddimers constituted an independent biomarker for poor prognosis in COVID-19 patients [8] .

Pathophysiology of this hyper-coagulation state remain incompletely understood and probably multifactorial favored by systemic inflammation and cytokine storm [7, 9] . Some authors also suggest existence of a specific vasculopathy due to direct vascular endothelial cell infection by SARS-CoV-2 through the angiotensin converting enzyme 2 receptor [10] .

Lupus anticoagulant (LAC) and anti-phospholipid antibodies (APAb) are known to increase thromboembolic risk and be associated with anti-phospholipid syndrome (APS) [11] . In COVID-19 patients little data are currently available [12] [13] [14] . However, little data available are interesting and should lead us to ask some questions. Indeed, in an article Zhang et al [12] report 3 cases of ischemic stroke with presence of APAb represented by anti-cardiolipin (aCL) and anti-β2-glycoprotein I (aβ2GPI) in COVID-19 patients without history of APS. In another article, Beyrouti et al [13] signs. In this case, anticoagulant therapy is usually not necessary [11] . However, detection of LAC with or without aCL or aβ2GPI in symptomatic COVID-19 patients characterized by significant increased risk of thromboembolic events highlight the importance of an early detection for better therapeutic management. Implication of LAC or APAb in COVID-19 pathophysiology remain poorly understood. However, it could be involved and their procoagulant action could be involved in thromboembolic events due to COVID-19, in particular in ischemic stroke. From our point of view, more studies are necessary to elucidate roles of LAC and APAb in COVID-19. However, it may be interesting to look for LAC and APAb in our COVID-19 patients with thrombotic event or high D-Dimeres level to adapt anticoagulation level. Current data suggest use of prophylactic anticoagulation with low-molecular-weightheparin in hospitalized COVID-19 patients [7] . Full intensity anticoagulation should not be used unless otherwise indicated such as positivity of LAC and / or APAb [11] .

Financial disclosure: None. There is no sponsor for the study.

Author contributions: All authors affirm that they have contributed equally to the production of this manuscript.

The authors declare that they have no conflict of interests.

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Acute Cerebrovascular Disease Following COVID-19: A Single Center, Retrospective, Observational Study

Neurologic Features in Severe SARS-CoV-2 Infection

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

COVID-19 and its implications for thrombosis and anticoagulation

Changes in Blood Coagulation in Patients with Severe Coronavirus Disease 2019 (COVID-19): a Meta-Analysis

COVID-19 Coagulopathy in Caucasian patients

Endothelial cell infection and endotheliitis in COVID-19

Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome

Antiphospholipid Antibodies in Patients with Covid-19

Characteristics of ischaemic stroke associated with COVID-19